Business
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology Congress
Toronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSG...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology CongressToronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is pleased to announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract summarizes the results to date of the second clinical study that Telo is conducting in collaboration with the Mayo Clinic. The study's objective is to validate the utility of TeloView technology in identifying newly diagnosed multiple myeloma (NDMM) patients, who might develop resistance to first line therapy within 12 months from the point of diagnosis. The study also aims to confirm multiple myeloma (MM) disease stability for patients who go into remission. This important subgroup may have a low probability to relapse for up to 3 years, over which time they can me monitored with TeloView. The results summarized in the abstract are under embargo until the abstract is published online on the EHA website on May 11, 2023.Acceptance of the NDMM study data for presentation and publication at EHA 2023 highlights Telo's successful path in establishing TeloView technology as an important predictive/prognostic tool in the management of MM across several stages of the disease. Telo has recently announced that the results of its smoldering multiple myeloma (SMM) clinical study, also conducted in collaboration with the Mayo Clinic, were accepted for presentation and publication at the American Society for Clinical Oncology (ASCO) 2023 annual meeting, to be held from June 2-6th, 2023Telo's lead product is designed to identify high-risk SMM patients who may receive earlier treatment intervention before the patient develops symptoms from active MM. Notably, the test will also benefit the larger subset of low-risk SMM patients, who have a more stable form of the disease, and do not require immediate treatment. These patients can be regularly monitored using Telo's test, importantly, stable SMM patients may be tested up to every three months. The Company's second assay is designed to identify NDMM patients who are most likely to develop treatment resistance and...